These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36951436)

  • 1. Impact of residual disease biomarkers on the prognosis of HER2-positive breast cancer following neoadjuvant therapy.
    Ma Y; Zhu M; Lv M; Yuan P; Chen X; Liu Z
    Cancer Med; 2023 May; 12(10):11293-11304. PubMed ID: 36951436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer.
    Kutlu Y; Cekin R; Aydin SG; Shbair ATM; Bilici A; Arici S; Oven BB; Acikgoz O; Ozcan E; Olmez OF; Cakir A; Seker M
    Curr Probl Cancer; 2024 Jun; 50():101102. PubMed ID: 38735211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
    Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
    PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.
    Schettini F; Nucera S; Brasó-Maristany F; De Santo I; Pascual T; Bergamino M; Galván P; Conte B; Seguí E; García Fructuoso I; Gómez Bravo R; Rivera P; Rodríguez AB; Martínez-Sáez O; Ganau S; Sanfeliu E; González-Farre B; Vidal Losada MJ; Adamo B; Cebrecos I; Mension E; Oses G; Jares P; Vidal-Sicart S; Mollà M; Muñoz M; Prat A
    ESMO Open; 2024 Jul; 9(7):103619. PubMed ID: 38943737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study.
    Tang L; Jiang L; Shu X; Jin Y; Yu H; Liu S
    Sci Rep; 2024 May; 14(1):11761. PubMed ID: 38783028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
    Qiao W; Guo W; Liu Q; Guo X; Deng M
    Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances.
    Yilmaz C; Cavdar DK
    Curr Oncol; 2022 Dec; 29(12):9695-9710. PubMed ID: 36547175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer.
    Teleki I; Krenacs T; Szasz MA; Kulka J; Wichmann B; Leo C; Papassotiropoulos B; Riemenschnitter C; Moch H; Varga Z
    BMC Cancer; 2013 Feb; 13():50. PubMed ID: 23374644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations.
    Yan S; Zhao W; Dong Y; Wang H; Xu S; Yu T; Tao W
    World J Surg Oncol; 2024 Sep; 22(1):248. PubMed ID: 39267055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
    Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
    Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes.
    Wetzel CL; Sutton TL; Gardiner S; Farinola M; Johnson N; Garreau JR
    J Surg Oncol; 2021 Dec; 124(8):1224-1234. PubMed ID: 34416025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    Montagna E; Bagnardi V; Viale G; Rotmensz N; Sporchia A; Cancello G; Balduzzi A; Galimberti V; Veronesi P; Luini A; Mastropasqua MG; Casadio C; Sangalli C; Goldhirsch A; Colleoni M
    Ann Oncol; 2015 Feb; 26(2):307-13. PubMed ID: 25411418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of neoadjuvant therapy on breast cancer biomarker profile.
    Rey-Vargas L; Mejía-Henao JC; Sanabria-Salas MC; Serrano-Gomez SJ
    BMC Cancer; 2020 Jul; 20(1):675. PubMed ID: 32682413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
    Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
    Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors of patients with human epidermal growth factor receptor 2-positive breast cancer following neoadjuvant therapy: Development and validation of a predictive nomogram.
    Jia Z; Xing H; Wang J; Wang X; Wang X; Liu C; He J; Wu S; Miao J; Liu H; Liu Y
    Pathol Res Pract; 2024 Sep; 261():155504. PubMed ID: 39116570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.
    Trifunovic J; Memisevic N; Nikolin B; Salma S; Dugandzija T; Vidovic V
    J BUON; 2017; 22(2):638-643. PubMed ID: 28730768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.